Products on this site are sold strictly for laboratory and research use only — not for human or veterinary consumption. You must be 21 or older to enter.
By entering you acknowledge our Terms and intended-use policy.30% off everything Buy 1, get 1 free on select vials
The "Wolverine peptide" is BPC-157 and TB-500 together. This BPC-157 / TB-500 blend holds both in equal parts in one lyophilised vial, 10 mg or 20 mg, each size with its own ILS Laboratories certificate.
Verified test results
Each batch is analyzed by an ISO/IEC 17025 accredited third-party laboratory before it ships. This is the released report for the size selected above, exactly as the lab signed it.
Certificate of analysis
99.26%
Purity by HPLC
Full QC panel
5 passed · 2 reportedPurity
HPLC · spec ≥ 95.0%
Net Blend Peptide Content
Identity
HPLC-RTM
Fentanyl Screen
Heavy Metals
ICP-MS
Sterility
PCR
Endotoxin
USP <85>
Certificate of analysis
99.76%
Purity by HPLC
Full QC panel
5 passed · 2 reportedPurity
HPLC · spec ≥ 95.0%
Net Blend Peptide Content
Identity
HPLC-RTM
Fentanyl Screen
Heavy Metals
ICP-MS
Sterility
PCR
Endotoxin
USP <85>
Open any size’s signed certificate. Your order ships with the report for the size you buy.
LOT Batch ACE-4051344
99.26%
HPLC purity · meets spec
5 assays passed · ILS Laboratories, ISO/IEC 17025 accredited
LOT ACE-7008874
99.76%
HPLC purity · meets spec
5 assays passed · ILS Laboratories, ISO/IEC 17025 accredited
“Wolverine” is a market nickname for the pairing of two research peptides: BPC-157, a 15-residue fragment of a gastric juice protein, and TB-500, the N-acetylated actin-binding fragment of thymosin beta-4. Sellers use it for this two-peptide blend and for the same pair bought as separate vials, which is usually called the Wolverine stack. The name is not consistent everywhere: FDA’s 2026 briefing quotes one website applying it to BPC-157 alone.
This blend is a 1:1 mixture by mass. On the current certificates, the 10 mg vial measured 5.25 mg of each peptide and the 20 mg vial 10.45 mg of each.
| BPC-157 | TB-500 | |
|---|---|---|
| What it is | Synthetic 15-residue fragment of a human gastric juice protein (“body protection compound”) |
N-acetylated fragment 17–23 of thymosin beta-4, its actin-binding region |
| Sequence | GEPPPGKPADDAGLV |
Ac-LKKTETQ |
| Molecular formula | C62H98N16O22 |
C38H68N10O14 |
| Molecular weight | 1419.5 g/mol |
889.0 g/mol |
| CAS number | 137525-51-0 |
885340-08-9 |
| PubChem CID | ||
| Parent protein | A gastric juice protein (“BPC”); no UniProt entry |
Thymosin beta-4, UniProt P62328 |
TB-500 is not the same substance as full-length thymosin beta-4 (43 residues). FDA’s 2026 briefing makes the point explicitly, and human trials of thymosin beta-4 should not be read as TB-500 evidence.
Both sizes were analysed by ILS Laboratories in San Diego, which states ISO/IEC 17025 accreditation for activities within its published scope. Each certificate confirms both peptides by HPLC retention time and measures the content of each:
| Size | Lot | Laboratory | Analysed | HPLC purity | Measured content | Identity |
|---|---|---|---|---|---|---|
| 10mg | ILS Laboratories | 18 Sep 2026 | 99.26% | 10.49mg (BPC-157 5.25mg + TB-500 5.25mg) | Confirmed | |
| 20mg | ILS Laboratories | 18 Sep 2026 | 99.76% | 20.9mg (BPC-157 10.45mg + TB-500 10.45mg) | Confirmed |
Transcribed from the certificate issued for each size on sale today. The certificate names the material as BPC-157 / TB-500. Open the signed certificate for any size under Verified test results above. Every BPC-157 / TB-500 Blend COA, lot by lot
Only one controlled study has tested the pair. In rats with a repaired Achilles tendon, TB-500 alone improved load to failure and histology scores against controls, BPC-157 alone improved numerically, and the combination showed no additional benefit over either peptide alone. The authors call it exploratory. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Biçer O, et al. Joint Diseases and Related Surgery, 2026.
Human data are thin. BPC-157 has three small uncontrolled reports from one US clinic; FDA found no clinical studies of TB-500 in humans.
Neither peptide is an approved drug. FDA placed both in its compounding safety-risk category in September 2023; they are now listed there as nominated-but-withdrawn, and at a July 2026 advisory meeting FDA proposed not adding either to the 503A bulks list. WADA’s 2026 Prohibited List names BPC-157 (S0) and TB-500 (S2.3). FDA compounding safety-risk list; WADA 2026 Prohibited List. This blend is a laboratory reference material only.
Every figure below is transcribed from the paperwork for this compound.
“Wolverine” is a market nickname for BPC-157 and TB-500 together. This product is that pair as a 1:1 blend in one vial.
Equal parts by mass of BPC-157 (GEPPPGKPADDAGLV) and TB-500 (Ac-LKKTETQ). The current 10 mg lot measured 5.25 mg of each; the 20 mg lot 10.45 mg of each.
No. TB-500 is the N-acetylated seven-residue fragment 17-23 of thymosin beta-4. Full-length thymosin beta-4 has 43 residues, and FDA notes the two are not the same substance.
One controlled study exists: a 2026 rat Achilles tendon study in which the combination showed no additional benefit over either peptide alone.
Same two peptides. The blend is both in one vial; the stack usually means BPC-157 and TB-500 bought as separate vials.
10 mg and 20 mg vials. Each size has its own ILS Laboratories certificate on this page.
Each size ships against the certificate issued for its own fill — purity, identity and batch, on file before you buy.
Shop the catalog
